Trial record 1 of 1 for:    millennium C25003
Previous Study | Return to List | Next Study

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Millennium Pharmaceuticals, Inc.
Sponsor:
Collaborator:
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01712490
First received: October 19, 2012
Last updated: October 20, 2014
Last verified: October 2014

October 19, 2012
October 20, 2014
November 2012
December 2019   (final data collection date for primary outcome measure)
Modified progression free survival (mPFS) per independent review facility (IRF) [ Time Frame: Date of randomization to mPFS event, for approximately 3 to 5 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01712490 on ClinicalTrials.gov Archive Site
Overall survival rate [ Time Frame: Date of randomization to the date of death, for approximately 5 to 7 years ] [ Designated as safety issue: No ]
Date of randomization to the date of death
Same as current
Not Provided
Not Provided
 
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hodgkin Lymphoma
  • Drug: brentuximab vedotin
    Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle
    Other Names:
    • ADCETRIS®
    • SGN-35
  • Drug: doxorubicin
    Doxorubicin: 25 mg/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
    Other Name: Adriamycin
  • Drug: bleomycin
    Bleomycin: 10 units/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
  • Drug: vinblastine
    Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
  • Drug: dacarbazine
    Dacarbazine (DTIC): 375 mg/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
    Other Name: DTIC
  • Experimental: A + AVD
    A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 mg/kg plus doxorubicin 25 mg/m2, vinblastine 6 mg/m2, and dacarbazine (DTIC) 375 mg/m2
    Interventions:
    • Drug: brentuximab vedotin
    • Drug: doxorubicin
    • Drug: vinblastine
    • Drug: dacarbazine
  • Active Comparator: ABVD
    ABVD consists of doxorubicin 25 mg/m2, bleomycin 10 units/m2, vinblastine 6 mg/m2, and dacarbazine (DTIC) 375 mg/m2
    Interventions:
    • Drug: doxorubicin
    • Drug: bleomycin
    • Drug: vinblastine
    • Drug: dacarbazine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1040
March 2020
December 2019   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Treatment-naïve
  • Histologically confirmed classical Hodgkin Lymphoma (HL)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Bidimensional measurable disease

Exclusion Criteria:

  • Nodular lymphocyte predominant Hodgkin lymphoma
  • Cerebral/meningeal disease, including signs and symptoms of progressive multifocal leukoencephalopathy (PML)
  • Pulmonary diffusion capacity > 25% lower than normal predicted value
  • Sensory or motor peripheral neuropathy
  • Known human immunodeficiency virus (HIV) positive
  • Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection

Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.

Both
18 Years and older
No
Contact: For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center 1-877-674-3784 medical@mlnm.com
United States,   Turkey,   Canada,   France,   Italy,   Japan,   Korea, Republic of,   Norway,   Poland,   South Africa
 
NCT01712490
C25003, 2011-005450-60, U1111-1161-4937, 12/LO/1950, JapicCTI-142491
Yes
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP